Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: AbbVie Ltd., Maidenhead, SL6 4UB, UK
Chirocaine 5 mg/ml solution for injection/concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Solution for injection/concentrate for solution for infusion. Clear colourless solution. |
One ml contains 5 mg levobupivacaine as levobupivacaine hydrochloride.
Each ampoule contains 50 mg in 10 ml.
Excipients with known effect: 3.5 mg/ml of sodium per ampoule.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Levobupivacaine |
Levobupivacaine is a long acting local anaesthetic and analgesic. It blocks nerve conduction in sensory and motor nerves largely by interacting with voltage sensitive sodium channels on the cell membrane, but also potassium and calcium channels are blocked. In addition, levobupivacaine interferes with impulse transmission and conduction in other tissues where effects on the cardiovascular and central nervous systems are most important for the occurrence of clinical adverse reactions. |
| List of Excipients |
|---|
|
Sodium chloride |
Chirocaine is available in two presentations:
Not all pack sizes may be marketed.
AbbVie Ltd., Maidenhead, SL6 4UB, UK
PL41042/0006
Date of first authorisation: 06th January 2000
Date of last renewal: 18th December 2013
| Drug | Countries | |
|---|---|---|
| CHIROCAINE | Finland, France, Hong Kong, Ireland, Lithuania, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
